Pre-order Enquiry
Download Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflammation-causing substance. TNF inhibitor drugs are employed to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. Generally, in the healthy person, the TNF levels remain steady. However, in a patient with rheumatoid arthritis, the level of TNF is increasing which leads to more inflammation. TNF inhibitor drugs act as blockers for TNF substances. TNF alpha blockers are highly effective in the treatment of patients with active rheumatoid arthritis. These drugs are used in patients as a conventional second-line treatments.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for TNF Inhibitors estimated at US$ 42740 million in the year 2022, is projected to reach a revised size of US$ 45750 million by 2028, growing at a CAGR of 1.1% during the forecast period 2022-2028.
The adalimumab segment is likely to expand at a significant pace during the forecast period. The drug is effectively used in a broad range of pain management therapies and is widely available over the counter. Based on distribution channel, the TNF inhibitors market can be segmented into hospital pharmacy and retail pharmacy. The hospital pharmacy segment is likely to expand at a significant pace between 2017 and 2025, this is because patients with rheumatoid arthritis, arthritis give more preference to the hospitals for treatment. Increase in elderly population and rise in the prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are some of the factors that drive the TNF inhibitors market. According to the National Health Interview Survey, in 2016, almost 20% of the global population was reported to be suffering from chronic pain, with rheumatoid arthritis being one of the major reasons. Moreover, according to the Center for Disease Control and Prevention, by 2040, approximately 78 million (26%) of the U.S. adults are projected to have arthritis. Owing to this, the consumption of TNF inhibitor dugs is likely to increase rapidly in the near future. However, side-effects associated with the use of TNF inhibitor drugs such as skin irritation, flushing, headache, and abdominal pain are estimated to hinder the market in the next few years.
Report Scope
This latest report researches the industry structure, revenue and gross margin.
This report also includes a discussion of the major players across each regional TNF Inhibitors market. Further, it explains the major drivers and regional dynamics of the global TNF Inhibitors market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Pfizer
Novartis
Boehringer Ingelheim
Amgen
BioPharma
Mochida Pharmaceutical
Hanall
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
TNF Inhibitors
Segment by Type
Monotherapy
Combination Therapy
TNF Inhibitors
Segment by Application
Skin Disease
Ankylosing Spondylitis
Gastrointestinal Disease
Rheumatoid Arthritis
Others
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the TNF Inhibitors market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for TNF Inhibitors market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of TNF Inhibitors, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for TNF Inhibitors, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the TNF Inhibitors revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global TNF Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for TNF Inhibitors revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Novartis, Boehringer Ingelheim, Amgen, BioPharma, Mochida Pharmaceutical and Hanall, etc.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for TNF Inhibitors estimated at US$ 42740 million in the year 2022, is projected to reach a revised size of US$ 45750 million by 2028, growing at a CAGR of 1.1% during the forecast period 2022-2028.
The adalimumab segment is likely to expand at a significant pace during the forecast period. The drug is effectively used in a broad range of pain management therapies and is widely available over the counter. Based on distribution channel, the TNF inhibitors market can be segmented into hospital pharmacy and retail pharmacy. The hospital pharmacy segment is likely to expand at a significant pace between 2017 and 2025, this is because patients with rheumatoid arthritis, arthritis give more preference to the hospitals for treatment. Increase in elderly population and rise in the prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are some of the factors that drive the TNF inhibitors market. According to the National Health Interview Survey, in 2016, almost 20% of the global population was reported to be suffering from chronic pain, with rheumatoid arthritis being one of the major reasons. Moreover, according to the Center for Disease Control and Prevention, by 2040, approximately 78 million (26%) of the U.S. adults are projected to have arthritis. Owing to this, the consumption of TNF inhibitor dugs is likely to increase rapidly in the near future. However, side-effects associated with the use of TNF inhibitor drugs such as skin irritation, flushing, headache, and abdominal pain are estimated to hinder the market in the next few years.
Report Scope
This latest report researches the industry structure, revenue and gross margin.
Major players
’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the TNF Inhibitors companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.This report also includes a discussion of the major players across each regional TNF Inhibitors market. Further, it explains the major drivers and regional dynamics of the global TNF Inhibitors market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Pfizer
Novartis
Boehringer Ingelheim
Amgen
BioPharma
Mochida Pharmaceutical
Hanall
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
TNF Inhibitors
Segment by Type
Monotherapy
Combination Therapy
TNF Inhibitors
Segment by Application
Skin Disease
Ankylosing Spondylitis
Gastrointestinal Disease
Rheumatoid Arthritis
Others
Key Regions
& CountriesThis section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the TNF Inhibitors market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for TNF Inhibitors market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of TNF Inhibitors, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for TNF Inhibitors, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the TNF Inhibitors revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global TNF Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for TNF Inhibitors revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Novartis, Boehringer Ingelheim, Amgen, BioPharma, Mochida Pharmaceutical and Hanall, etc.
Frequently Asked Questions
This market study covers the global and regional market with an
in-depth analysis of the
overall growth prospects...
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by
highlighting information on
different aspects including drivers, restraints...
